These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

454 related items for PubMed ID: 24342522

  • 1. Rationale and design of the DIPAK 1 study: a randomized controlled clinical trial assessing the efficacy of lanreotide to Halt disease progression in autosomal dominant polycystic kidney disease.
    Meijer E, Drenth JP, d'Agnolo H, Casteleijn NF, de Fijter JW, Gevers TJ, Kappert P, Peters DJ, Salih M, Soonawala D, Spithoven EM, Torres VE, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, DIPAK Consortium.
    Am J Kidney Dis; 2014 Mar; 63(3):446-55. PubMed ID: 24342522
    [Abstract] [Full Text] [Related]

  • 2. Effect of Lanreotide on Kidney Function in Patients With Autosomal Dominant Polycystic Kidney Disease: The DIPAK 1 Randomized Clinical Trial.
    Meijer E, Visser FW, van Aerts RMM, Blijdorp CJ, Casteleijn NF, D'Agnolo HMA, Dekker SEI, Drenth JPH, de Fijter JW, van Gastel MDA, Gevers TJ, Lantinga MA, Losekoot M, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Wetzels JF, Zietse R, Gansevoort RT, DIPAK-1 Investigators.
    JAMA; 2018 Nov 20; 320(19):2010-2019. PubMed ID: 30422235
    [Abstract] [Full Text] [Related]

  • 3. Hepatic Cyst Infection During Use of the Somatostatin Analog Lanreotide in Autosomal Dominant Polycystic Kidney Disease: An Interim Analysis of the Randomized Open-Label Multicenter DIPAK-1 Study.
    Lantinga MA, D'Agnolo HM, Casteleijn NF, de Fijter JW, Meijer E, Messchendorp AL, Peters DJ, Salih M, Spithoven EM, Soonawala D, Visser FW, Wetzels JF, Zietse R, Drenth JP, Gansevoort RT, DIPAK Consortium.
    Drug Saf; 2017 Feb 20; 40(2):153-167. PubMed ID: 27995519
    [Abstract] [Full Text] [Related]

  • 4. Effect of lanreotide on polycystic liver and kidneys in autosomal dominant polycystic kidney disease: an observational trial.
    Gevers TJ, Hol JC, Monshouwer R, Dekker HM, Wetzels JF, Drenth JP.
    Liver Int; 2015 May 20; 35(5):1607-14. PubMed ID: 25369108
    [Abstract] [Full Text] [Related]

  • 5. Lanreotide Reduces Liver Growth In Patients With Autosomal Dominant Polycystic Liver and Kidney Disease.
    van Aerts RMM, Kievit W, D'Agnolo HMA, Blijdorp CJ, Casteleijn NF, Dekker SEI, de Fijter JW, van Gastel M, Gevers TJ, van de Laarschot LFM, Lantinga MA, Losekoot M, Meijer E, Messchendorp AL, Neijenhuis MK, Pena MJ, Peters DJM, Salih M, Soonawala D, Spithoven EM, Visser FW, Wetzels JF, Zietse R, Gansevoort RT, Drenth JPH, DIPAK-1 Investigators.
    Gastroenterology; 2019 Aug 20; 157(2):481-491.e7. PubMed ID: 31022403
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Rationale and design of the RESOLVE trial: lanreotide as a volume reducing treatment for polycystic livers in patients with autosomal dominant polycystic kidney disease.
    Gevers TJ, Chrispijn M, Wetzels JF, Drenth JP.
    BMC Nephrol; 2012 Apr 04; 13():17. PubMed ID: 22475206
    [Abstract] [Full Text] [Related]

  • 8. Lanreotide reduces the volume of polycystic liver: a randomized, double-blind, placebo-controlled trial.
    van Keimpema L, Nevens F, Vanslembrouck R, van Oijen MG, Hoffmann AL, Dekker HM, de Man RA, Drenth JP.
    Gastroenterology; 2009 Nov 04; 137(5):1661-8.e1-2. PubMed ID: 19646443
    [Abstract] [Full Text] [Related]

  • 9. Rapid Progression of Autosomal Dominant Polycystic Kidney Disease: Urinary Biomarkers as Predictors.
    Messchendorp AL, Meijer E, Visser FW, Engels GE, Kappert P, Losekoot M, Peters DJM, Gansevoort RT, on behalf of the DIPAK-1 study investigators.
    Am J Nephrol; 2019 Nov 04; 50(5):375-385. PubMed ID: 31600749
    [Abstract] [Full Text] [Related]

  • 10. Pansomatostatin Agonist Pasireotide Long-Acting Release for Patients with Autosomal Dominant Polycystic Kidney or Liver Disease with Severe Liver Involvement: A Randomized Clinical Trial.
    Hogan MC, Chamberlin JA, Vaughan LE, Waits AL, Banks C, Leistikow K, Oftsie T, Madsen C, Edwards M, Glockner J, Kremers WK, Harris PC, LaRusso NF, Torres VE, Masyuk TV.
    Clin J Am Soc Nephrol; 2020 Sep 07; 15(9):1267-1278. PubMed ID: 32843370
    [Abstract] [Full Text] [Related]

  • 11. Effect of Statin Therapy on the Progression of Autosomal Dominant Polycystic Kidney Disease. A Secondary Analysis of the HALT PKD Trials.
    Brosnahan GM, Abebe KZ, Rahbari-Oskoui FF, Patterson CG, Bae KT, Schrier RW, Braun WE, Chapman AB, Flessner MF, Harris PC, Perrone RD, Steinman TI, Torres VE, HALT PKD Investigators.
    Curr Hypertens Rev; 2017 Sep 07; 13(2):109-120. PubMed ID: 28460625
    [Abstract] [Full Text] [Related]

  • 12. Yinang formulation versus placebo granules as a treatment for chronic kidney disease stages III-IV in patients with autosomal dominant polycystic kidney disease: study protocol for a double-blind placebo-controlled randomized clinical trial.
    Gan J, Wu Y, Gong X, Ma Y, Yu S, Gao J.
    Trials; 2019 Aug 07; 20(1):481. PubMed ID: 31391092
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.
    Hogan MC, Masyuk TV, Page LJ, Kubly VJ, Bergstralh EJ, Li X, Kim B, King BF, Glockner J, Holmes DR, Rossetti S, Harris PC, LaRusso NF, Torres VE.
    J Am Soc Nephrol; 2010 Jun 07; 21(6):1052-61. PubMed ID: 20431041
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.